Research programme: IL-10 INDUKINE molecules - Werewolf Therapeutics
Latest Information Update: 08 May 2024
At a glance
- Originator Werewolf Therapeutics
- Class Anti-inflammatories; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 10 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammatory bowel diseases